Assessment of the Relative Bioavailability of Immediate Release Formulations of ABBV-903 in Healthy Volunteers
Latest Information Update: 19 Jul 2023
At a glance
- Drugs ABBV 903 (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Pharmacokinetics
- Sponsors AbbVie
Most Recent Events
- 13 Jul 2023 Status changed from active, no longer recruiting to completed.
- 18 May 2023 Planned End Date changed from 19 Jun 2023 to 20 Jun 2023.
- 18 May 2023 Planned primary completion date changed from 19 Jun 2023 to 20 Jun 2023.